Charles River Laboratories International CRL
NYSE CRL
$282.06 +8.65 (+3.16%)
As of: Sep 17, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) EBT Growth (3y) (2012 - 2026)

Analysis

Charles River Laboratories International (CRL) EBT Growth (3y) (2012 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Growth (3y) (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn -7.07%
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn 26.04%
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn -9.70%
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn -25.51%
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn -26.68%
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn 30.89%
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn 45.32%
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn -13.16%
10 VivoSim Labs 1.37 Mn 1.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 27, 2026 -25.51%
Mar 28, 2026 -30.62%
Dec 27, 2025 -47.37%
Sep 27, 2025 -10.86%
Jun 28, 2025 -20.87%
Mar 29, 2025 -31.28%
Dec 28, 2024 -49.25%
Sep 28, 2024 -9.54%
Jun 29, 2024 -2.09%
Mar 30, 2024 14.30%
Dec 30, 2023 6.57%
Sep 30, 2023 -5.86%
Jul 1, 2023 15.29%
Apr 1, 2023 33.19%
Dec 31, 2022 32.38%
Sep 24, 2022 18.90%
Jun 25, 2022 34.68%
Mar 26, 2022 18.69%
Dec 25, 2021 29.67%
Sep 25, 2021 18.92%